WXXWY:OTC-WuXi Biologics (Cayman) Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.7

Change

+0.03 (+0.82)%

Market Cap

USD 7.17B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

-0.12 (-0.12%)

USD 36.53B
UCBJF UCB SA

N/A

USD 35.59B
ARGNF argenx SE

N/A

USD 33.74B
GNMSF Genmab A/S

-2.12 (-0.95%)

USD 14.31B
WXIBF WuXi Biologics

N/A

USD 10.26B
IVBIY IVBIY

N/A

USD 9.55B
ZLDPF Zealand Pharma A/S

N/A

USD 8.66B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 8.61B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 8.60B
AKESF Akeso, Inc.

N/A

USD 8.00B

ETFs Containing WXXWY

3182:HK W.I.S.E-Nasdaq Overseas C.. 2.91 % 0.00 %

-0.22 (-2.10%)

N/A
CN Xtrackers MSCI All China .. 0.00 % 0.28 %

-0.01 (-2.10%)

N/A
EEMO Invesco S&P Emerging Mark.. 0.00 % 0.27 %

-0.14 (-2.10%)

N/A
FXI iShares China Large-Cap E.. 0.00 % 0.74 %

-0.41 (-2.10%)

N/A
MCHI iShares MSCI China ETF 0.00 % 0.59 %

-0.61 (-2.10%)

USD 6.34B
EMSG DBX ETF Trust - Xtrackers.. 0.00 % 0.00 %

-0.21 (-2.10%)

USD 0.03B
CHIL 0.00 % 0.00 %

N/A

N/A
CEA1:LSE iShares VII Public Limite.. 0.00 % 0.00 %

-157.00 (-2.10%)

N/A
DBRC:LSE iShares BRIC 50 UCITS 0.00 % 0.00 %

-0.37 (-2.10%)

N/A
EIMU:LSE iShares Core MSCI EM IMI .. 0.00 % 0.00 %

-0.04 (-2.10%)

N/A
FXC:LSE iShares China Large Cap U.. 0.00 % 0.00 %

-125.50 (-2.10%)

N/A
HMAD:LSE HSBC ETFs Public Limited .. 0.00 % 0.00 %

-0.67 (-2.10%)

N/A
HMCD:LSE HSBC MSCI China UCITS ETF 0.00 % 0.00 %

-0.12 (-2.10%)

N/A
HMFE:LSE 0.00 % 0.00 %

N/A

N/A
IDFX:LSE iShares China Large Cap U.. 0.00 % 0.00 %

-1.53 (-2.10%)

N/A
IEEM:LSE iShares MSCI Emerging Mar.. 0.00 % 0.00 %

-40.50 (-2.10%)

N/A
IFFF:LSE iShares Public Limited Co.. 0.00 % 0.00 %

-56.50 (-2.10%)

N/A
SAEM:LSE iShares MSCI EM IMI ESG S.. 0.00 % 0.00 %

-0.05 (-2.10%)

N/A
SEDM:LSE iShares MSCI EM IMI ESG S.. 0.00 % 0.00 %

-0.06 (-2.10%)

N/A
HMEM:LSE HSBC MSCI Emerging Market.. 0.00 % 0.00 %

-0.12 (-2.10%)

N/A
HMFD:LSE 0.00 % 0.00 %

N/A

N/A
SUES:LSE iShares Sustainable MSCI .. 0.00 % 0.00 %

-6.63 (-2.10%)

N/A
SUSM:LSE iShares Sustainable MSCI .. 0.00 % 0.00 %

-0.05 (-2.10%)

N/A
UB30:LSE UBS MSCI Emerging Markets.. 0.00 % 0.00 %

-1.21 (-2.10%)

N/A
XCX6:LSE Xtrackers MSCI China UCIT.. 0.00 % 0.00 %

-22.00 (-2.10%)

USD 1.09B
XMME:LSE Xtrackers MSCI Emerging M.. 0.00 % 0.00 %

-0.58 (-2.10%)

N/A
XX25:LSE Xtrackers FTSE China 50 U.. 0.00 % 0.00 %

-44.50 (-2.10%)

USD 0.19B
XX2D:LSE Xtrackers - FTSE China 50.. 0.00 % 0.00 %

-0.56 (-2.10%)

USD 0.19B
KESG 0.00 % 0.00 %

N/A

N/A
EMXF iShares ESG Advanced MSCI.. 0.00 % 0.00 %

-0.49 (-2.10%)

USD 0.09B
VFEA:LSE Vanguard FTSE Emerging Ma.. 0.00 % 0.00 %

-0.78 (-2.10%)

USD 0.64B
EDG2:LSE iShares MSCI EM ESG Enhan.. 0.00 % 0.00 %

-0.05 (-2.10%)

USD 4.83B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -50.34% 20% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.34% 21% F 9% A-
Trailing 12 Months  
Capital Gain -67.83% 28% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -67.83% 28% F 14% F
Trailing 5 Years  
Capital Gain -61.58% 61% D- 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.58% 60% D- 32% F
Average Annual (5 Year Horizon)  
Capital Gain 11.57% 58% F 58% F
Dividend Return 11.57% 58% F 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 73.71% 53% F 39% F
Risk Adjusted Return 15.69% 65% D 50% F
Market Capitalization 7.17B 97% N/A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.